Streetbeat News

Price Targets

ANNX

HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Annexon (NASDAQ:ANNX) with a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 1:04 pm

CPRX

Catalyst Pharmaceuticals (NASDAQ:CPRX) has received diverse analyst ratings over the past quarter, with a shift towards more bullish sentiments in recent months. The average 12-month price target for CPRX has risen to $29.29, indicating a positive outlook from financial experts. Analysts from firms like Oppenheimer, Cantor Fitzgerald, Citigroup, B of A Securities, and HC Wainwright & Co. have maintained or announced buy ratings, with price targets ranging from $23.00 to $34.00. Catalyst Pharmaceuticals, a biopharmaceutical company, has shown impressive financial performance with significant revenue growth, high net margin, and strong ROE and ROA, positioning it favorably in the market.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

SQ

Recent evaluations by 17 analysts on Block (NYSE:SQ) show diverse outlooks, ranging from bullish to bearish. The average 12-month price target for SQ is now $88.47, up 12.99% from the previous $78.30, with high estimates reaching $100.00. Analyst actions include upgrades and maintenance of ratings, reflecting optimism in Block's performance and market position. Despite a market cap below industry averages, Block's revenue growth stands out at 24.13%, though it faces challenges in profitability and returns metrics.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

CUBE

Four financial analysts have recently shared mixed evaluations of CubeSmart (NYSE:CUBE), with ratings ranging from bullish to bearish. The average 12-month price target for CUBE has been raised to $46.5, indicating a 14.81% increase from the previous target. Analysts from Barclays, Evercore ISI Group, Deutsche Bank, and Jefferies have adjusted their ratings and price targets, reflecting changing market conditions and CubeSmart's performance. CubeSmart, a real estate investment trust focusing on self-storage facilities, has shown solid revenue growth and impressive profitability metrics, despite a market capitalization below industry benchmarks.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

REXR

Analysts have diverse views on Rexford Industrial Realty (REXR), with recent evaluations ranging from bullish to bearish. The average 12-month price target is $54.5, down from $57.00. Analyst actions include adjustments to ratings and price targets by Barclays, Truist Securities, JP Morgan, and Baird. Rexford, a REIT focusing on industrial properties in Southern California, has shown strong financial performance with notable revenue growth, high net margin, and efficient asset and equity management.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

SNX

TD Synnex (NYSE:SNX) has received consistent 'Indifferent' ratings from 4 analysts over the past three months, with a positive shift in the 12-month price target to $113.5, up 5.58% from $107.50. Analysts from Barclays, CFRA, RBC Capital, and JP Morgan have raised their price targets, reflecting a cautiously optimistic outlook despite TD Synnex's recent financial challenges, including a -11.33% revenue decline and below-industry-standard profitability metrics.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

MTCH

Piper Sandler analyst Matt Farrell has reiterated an Overweight rating on Match Group (MTCH) and maintained a $45 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:57 pm

ANNX

Wells Fargo analyst Derek Archila has maintained an Overweight rating on Annexon (NASDAQ:ANNX) and increased the price target from $11 to $12.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:56 pm

VRTS

Piper Sandler analyst Crispin Love has maintained an Overweight rating on Virtus Investment Partners (VRTS) and increased the price target from $264 to $275.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:55 pm

IPWR

Benchmark analyst David Williams maintains a Buy rating on Ideal Power (NASDAQ:IPWR) but lowers the price target from $18 to $14.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:52 pm